G-4460(G-4460) - 药物靶点：MYB_专利_临床

概要

基本信息

药物类型

ASO

别名

+ [5]

靶点

MYB

作用机制

c-myb抑制剂(原癌基因蛋白c-myb抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症-

非在研适应症

白血病费城染色体阳性慢性粒细胞白血病

原研机构

University of Pennsylvania

在研机构-

非在研机构

University of Pennsylvania

Genta, Inc.

Temple University Graduate School

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

使用我们的RNA技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

100 项与 G-4460 相关的临床结果

登录后查看更多信息

100 项与 G-4460 相关的转化医学

登录后查看更多信息

100 项与 G-4460 相关的专利（医药）

登录后查看更多信息

1

项与 G-4460 相关的文献（医药）

1999-06-01·Current opinion in molecular therapeutics

Technology evaluation: leukemia therapy, University of Pennsylvania.

Article

作者: Orr, R M

The University of Pennsylvania is developing an antisense oligonucleotide (AS ON) as a potential treatmentfor myelogenous leukemia. The 24-mer phosphorothioate (PS) ON targets the c-myb gene (codons 2 to 9), a regulator of transcription. In a pilot study, patient bone marrow was purged with the PS ON before being returned to the patient. In January 1997, it was reported that out of six evaluable patients, four demonstrated marked hematological remission with normalized white blood cell counts. A second phase I trial was initiated, in which myelogenous leukemia patients were treated with systemic infusions of the PS ON at doses of 0.3 to 2.0 mg/kg/dayfor 7 days. By January 1997, 18 patients had been treated, 12 showed stable disease and one patient in blast crisis experienced a transient reversal to the chronic phase of the disease. No dose-related toxicity was noted and c-myb mRNA and protein levels were halved. Preclinical studies in leukemic mice showed that the myb AS PS ON increased survival times 2- to 4-fold and reduced leukemic proliferation in the brain [229790]. The ON was originally developed and patented at Temple University and was being jointly developed by Lynx Therapeutics, however, this collaboration was terminated in 1996 [264351]. New phase I studies are starting in 1999, with INX-3001 (University of Pennsylvania c-myb AS PS) supported by the NIH and Inex Pharmaceuticals Corporation.

100 项与 G-4460 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白血病	临床1期	-	Genta, Inc.	-
白血病	临床1期	-	Temple University Graduate School	-
白血病	临床1期	美国	-	-
白血病	临床1期	-	University of Pennsylvania	-
费城染色体阳性慢性粒细胞白血病	临床1期	美国	Genta, Inc.	-